Get started
Work

The case for low-level BACE1 inhibition for the prevention of Alzheimer disease

Year: 2021
Type: review
DOI: 10.1038/s41582-021-00545-1
Authors: Eric McDade, Iryna Voytyuk, Paul Aisen, Randall J. Bateman, Maria C. Carrillo, Bart De Strooper, Christian Haass, Eric M. Reiman, Reisa Sperling, Pierre N. Tariot, Riqiang Yan, Colin L. Masters, Robert Vassar, Stefan F. Lichtenthaler
Institutions: Washington University in St. Louis, University of Cambridge, Vlaams Instituut voor Biotechnologie, VIB-KU Leuven Center for Brain & Disease Research, KU Leuven, University of Southern California, Alzheimer's Association, UCL Queen Square Institute of Neurology, University College London, German Center for Neurodegenerative Diseases, Munich Cluster for Systems Neurology, Ludwig-Maximilians-Universität München, Banner Alzheimer’s Institute, Brigham and Women's Hospital, Harvard University, University of Connecticut, UConn Health, The University of Melbourne, Florey Institute of Neuroscience and Mental Health, Northwestern University, TUM Klinikum, Technical University of Munich
Language: English
Subfield: Physiology
Field: Medicine
Open Access status: green
Awards: G2433915830, G3288777586, G3319346612, G4445424522, DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIA, G819547828, DIAN-TU: Next Generation Prevention Trial
OpenAlex ID: W3199353075
FWCI: 4.222
Cites: 106
Cited by: 139
Related to: 10